[1]
Eisenhofer, G.; Lenders, J.W.; Siegert, G.; Bornstein, S.R.; Friberg, P.; Milosevic, D.; Mannelli, M.; Linehan, W.M.; Adams, K.; Timmers, H.J.; Pacak, K. Plasma methoxytyramine: A novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status. Eur. J. Cancer, 2012, 48(11), 1739-1749.
[2]
Lenders, J.W.M.; Eisenhofer, G. Update on modern management of pheochromocytoma and paraganglioma. Endocrinol. Metab. (Seoul), 2017, 32(2), 152-161.
[3]
Druce, M.R.; Kaltsas, G.A.; Fraenkel, M.; Gross, D.J.; Grossman, A.B. Novel and evolving therapies in the treatment of malignant phaeochromocytoma: Experience with the mTOR inhibitor everolimus (RAD001). Horm. Metab. Res., 2009, 41(9), 697-702.
[4]
Jimenez, C.; Rohren, E.; Habra, M.A.; Rich, T.; Jimenez, P.; Ayala-Ramirez, M.; Baudin, E. Current and future treatments for malignant pheochromocytoma and sympathetic paraganglioma. Curr. Oncol. Rep., 2013, 15(4), 356-371.
[5]
Parenti, G.; Zampetti, B.; Rapizzi, E.; Ercolino, T.; Giache, V.; Mannelli, M. Updated and new perspectives on diagnosis, prognosis, and therapy of malignant pheochromocytoma/paraganglioma. J. Oncol., 2012. 872713
[6]
Zoncu, R.; Efeyan, A.; Sabatini, D.M. mTOR: From growth signal integration to cancer, diabetes and ageing. Nat. Rev. Mol. Cell Biol., 2011, 12(1), 21-35.
[7]
Kawasaki, G.; Naruse, T.; Furukawa, K.; Umeda, M. mTORC1 and mTORC2 expression levels in oral squamous cell carcinoma: An immunohistochemical and clinicopathological study. Anticancer Res., 2018, 38(3), 1623-1628.
[8]
Martelli, A.M.; Buontempo, F.; McCubrey, J.A. Drug discovery targeting the mTOR pathway. Clin. Sci. (Lond.), 2018, 132(5), 543-568.
[9]
Jebali, A.; Dumaz, N. The role of RICTOR downstream of receptor tyrosine kinase in cancers. Mol. Cancer, 2018, 17(1), 39.
[10]
Giubellino, A.; Bullova, P.; Nölting, S.; Turkova, H.; Powers, J.F.; Liu, Q.; Guichard, S.; Tischler, A.S.; Grossman, A.B.; Pacak, K. Combined inhibition of mTORC1 and mTORC2 signaling pathways is a promising therapeutic option in inhibiting pheochromocytoma tumor growth: in vitro and in vivo studies in female athymic nude mice. Endocrinology, 2013, 154(2), 646-655.
[11]
Facchinetti, V.; Ouyang, W.; Wei, H.; Soto, N.; Lazorchak, A.; Gould, C.; Lowry, C.; Newton, A.C.; Mao, Y.; Miao, R.Q.; Sessa, W.C. The mammalian target of rapamycin complex 2 controls folding and stability of Akt and protein kinase C. EMBO J., 2008, 23, 27(14), 1932-1943.
[12]
Zhang, X.; Wang, X.; Xu, T.; Zhong, S.; Shen, Z. Targeting of mTORC2 may have advantages over selective targeting of mTORC1 in the treatment of malignant pheochromocytoma. Tumour Biol., 2015, 36(7), 5273-5281.
[13]
Zhang, F.; Lazorchak, A.S.; Liu, D.; Chen, F.; Su, B. Inhibition of the mTORC2 and chaperone pathways to treat leukemia. Blood, 21, 119(25), 6080-6088.
[14]
Zhang, J.Y.; Tao, L.Y.; Liang, Y.J.; Chen, L.M.; Mi, Y.J.; Zheng, L.S.; Wang, F.; She, Z.G.; Lin, Y.C.; To, K.K.W.; Fu, L.W. Anthracenedione derivatives as anticancer agents isolated from secondary metabolites of the mangrove endophytic fungi. Mar. Drugs, 2010, 8, 1469-1481.
[15]
Zhang, X.; Wang, X.; Qin, L.; Xu, T.; Zhu, Z.; Zhong, S.; Zhang, M.; Shen, Z. The dual mTORC1 and mTORC2 inhibitor PP242 shows strong antitumor activity in a pheochromocytoma PC12 cell tumor model. Urology, 2015, 85(1), 273. e1-7
[16]
Sato, S.; Fujita, N.; Tsuruo, T. Modulation of Akt kinase activity by binding to Hsp90. Proc. Natl. Acad. Sci. USA, 2000, 97(20), 10832-10837.
[17]
Xu, Y.; Zhu, Q.; Chen, D.; Shen, Z.; Wang, W.; Ning, G.; Zhu, Y. The HSP90 inhibitor 17-AAG exhibits potent antitumor activity for pheochromocytoma in a xenograft model. Tumour Biol., 2015, 36(7), 5103-5108.
[18]
Banerji, U. Heat shock protein 90 as a drug target: Some like it hot. Clin. Cancer Res., 2009, 15(1), 9-14.
[19]
Xu, Y.; Qi, Y.; Rui, W.; Zhu, Y.; Zhang, C.; Zhao, J.; Wei, Q.; Wu, Y.; Shen, Z.; Ning, G. Expression and diagnostic relevance of heat shock protein 90 and signal transducer and activator of transcription 3 in malignant pheochromocytoma. J. Clin. Pathol., 2013, 66(4), 286-290.
[20]
Lian, J.; Lin, D.; Xie, X.; Xu, Y.; Xu, L.; Meng, L.; Zhu, Y. NVP-AUY922, a novel HSP90 inhibitor, inhibits the progression of malignant pheochromocytoma in vitro and in vivo. OncoTargets Ther., 2017, 10, 2219-2226.
[21]
Giubellino, A.; Sourbier, C.; Lee, M.J.; Scroggins, B.; Bullova, P.; Landau, M.; Ying, W.; Neckers, L.; Trepel, J.B.; Pacak, K. Targeting heat shock protein 90 for the treatment of malignant pheochromocytoma. PLoS One, 2013, 8(2)e56083